Evidence map›Paper›PMID 30301153›Full record

ArticleMolecules (Basel, Switzerland)2018

Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer's Disease.

Wenhao Wu, Xintong Liang, Guoquan Xie, Langdi Chen, Weixiong Liu, Guolin Luo, Peiquan Zhang, Lihong Yu, Xuehua Zheng, Hong Ji and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Wenhao WuKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. wenhao_wu@gzhmu.edu.cn.ORCID 0000-0003-0764-3781
Xintong LiangKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. kilyte18@163.com.
Guoquan XieKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. guoquanxie@163.com.
Langdi ChenKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. chenlangdi427@gmail.com.
Weixiong LiuKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. 13760781141@139.com.
Guolin LuoKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. 13570203692@163.com.
Peiquan ZhangKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. pqzhang@gzhmu.edu.cn.
Lihong YuKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. ylh84@126.com.
Xuehua ZhengKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. zhengxh23@gzhmu.edu.cn.
Hong JiKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. dljih@126.com.
Chao ZhangKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. chao-zh@163.com.
Wei YiKey Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, China. yiwei@gzhmu.edu.cn.ORCID 0000-0001-7936-9326
Guangzhou Medical University · CN

Funding

Guangzhou science and technology project 201707010008the Foundation of Educational Commission of Guangdong Province of China 2013KJCX0151the Foundation of Educational Commission of Guangdong Province of China 2014KTSCX096the Foundation of Educational Commission of Guangdong Province of China 2016KQNCX129
6 · The paper itself

Abstract

A series of novel ligustrazine derivatives

Indexed as

AcetylcholinesteraseAlzheimer DiseaseAmyloid beta-PeptidesAntioxidantsBinding SitesCatalytic DomainCholinesterase InhibitorsDrug DesignHumansKineticsMolecular Docking SimulationProtein Aggregation, PathologicalPyrazinesStructure-Activity RelationshipAcetylcholinesteraseAmyloid beta-PeptidesAntioxidantsCholinesterase InhibitorsPyrazinestetramethylpyrazineacetylcholinesteraseAlzheimer’s diseaseligustrazinemulti-targeted inhibitorsself-induced Aβ aggregation

Identifiers

PMID30301153
PMCPMC6222487
OpenAlexW2895564460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.